Drug Profile
Research programme: anti-cancer therapeutics - Incyte/Vanderbilt University Medical Center
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Incyte Corporation; Vanderbilt University Medical Center
- Developer Vanderbilt University Medical Center
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Cancer in USA
- 07 Jul 2015 Early research in Cancer in USA (unspecified route)